Metabolic Modulation as Treatment in Acute Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate whether metabolic modulation improves hemodynamics and outcome in acute heart failure

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acute heart failure is a serious disease that despite modern therapies carries a high mortality. Inotropic drugs improve patient status but yield a higher risk of death. Previous studies have shown that myocardial contractility improves when glucose fermentation is up regulated and decreases when Free Fatty Acids are high. In a placebo-controlled design we wish to shift myocardial substrate metabolism towards increased glucose uptake and utilization and measure hemodynamics and biochemical markers of metabolism and prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Heart Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Acute heart failure Metabolic modulation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acipimox

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute heart failure
* NYHA class III - IV.
* ejection fraction \<35

Exclusion Criteria

* Age \<18 år or \>85 år,
* allergy
* renal failure
* recently developed brady- or tachy-arrythmias
* Serious infection
* Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease
* Recent Myocardial infarction (\<6 Weeks)
* Pulmonary Wedge pressure \>30 mm Hg
* diabetes mellitus treated with insulin
* peptic ulcer
* pregnancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mads Halbirk, dr.

Role: PRINCIPAL_INVESTIGATOR

Aarhus University Hospital, Department of Cardiology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aarhus University Hospital, Skejby Sygehus, Department of Cardiology

Aarhus, Aarhus, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20060810

Identifier Type: -

Identifier Source: org_study_id